M

MedPacto Inc
KOSDAQ:235980

Watchlist Manager
MedPacto Inc
KOSDAQ:235980
Watchlist
Price: 6 560 KRW -14.81% Market Closed
Market Cap: ₩224.9B

MedPacto Inc
Investor Relations

MedPacto, Inc. researches and develops anti-cancer drugs. The company is headquartered in Seoul, Seoul. The company went IPO on 2019-12-19. The firm researches and develops anticancer drugs and diagnostic kits including vactosertib, MA-B2 and others. The products are used as the treatment of multiple myeloma, lung cancer, stomach cancer, colon cancer, blood cancer, triple negative breast cancer and pancreatic cancer, among others.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. Seong-Jin Kim
Founder & CEO
No Bio Available
Mr. Ki Baik Hahm M.D., Ph.D.
Executive Vice President of R&D
No Bio Available
Mr. Sunjin Hwang M.D.
Chief Medical Officer
No Bio Available
Dr. Timothy R. Allen
Executive Vice President of Clinical Development at MedPacto Therapeutics - U.S.
No Bio Available

Contacts

Address
SEOUL
Seoul
Borim Bldg., 92, Myeongdal-ro, Seocho-gu
Contacts
+82269380200
www.medpacto.com